BioAmber BIOA 深 沪
已收盘 12-19 16:00:00 美东时间
13.375
+0.995
+8.04%
华盛通- 最 高13.408
- 今 开12.41
- 成交量 57.88万股
- 最 低 8.46
- 昨 收 12.38
- 总市值 0
- 52周最高 13.408
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 2.88
- 委 比 45.56%
- 总股本 --
- 历史最高 26.62
- 量 比 2.09
- 振 幅 39.97%
- 历史最低 0.156
- 每 手 1
- 风险率 1.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
BioAge Labs的数据显示，其apelin受体激动剂在治疗糖尿病肥胖和心力衰竭方面具有潜力，可增强血糖控制并提供心脏保护效应，尤其与葡萄糖依赖性促胰岛素多肽（incretin）疗法联合使用时效果更佳。这些发现支持开发下一代药物以应对肥胖及其相关疾病。
06-21 22:00
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
BioAge Labs collaborates with Age Labs AS to analyze over 17,000 samples from the HUNT Biobank, aiming to discover drug targets for aging-related diseases. Using proteomic data and machine learning, they seek insights into resilience and disease progression to identify novel therapies.
06-17 13:00
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
BioAge Labs collaborates with JiKang Therapeutics to license a novel APJ agonist antibody and files a patent for small molecule APJ agonists, targeting metabolic diseases and obesity with potential pharmacological exercise mimetics to enhance weight loss.
06-03 13:00
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla's Ozuriftamab Vedotin (Oz-V) shows 45% ORR and 100% DCR in HPV+ OPSCC patients with 3 prior therapies. Current treatments have 3.4% ORR. BioAtla plans Phase 3 trial discussions with FDA for 2L+ HPV+ OPSCC.
06-02 12:00
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs will participate in upcoming investor conferences: Jefferies Global Healthcare Conference (June 3–5, 2025) and Goldman Sachs Global Healthcare Conference (June 9–11, 2025). Kristen Fortney and Dov Goldstein will attend, with Fortney scheduled for a fireside chat on June 9.
05-27 20:30
Morgan Stanley Assumes Bioage Labs at Underweight, Announces Price Target of $5
Morgan Stanley analyst Jeffrey Hung assumes Bioage Labs (NASDAQ:BIOA) with a Underweight rating and announces Price Target of $5.
03-08 01:11
